ZA200804694B - Four branched dendrimer-peg for conjugation to proteins and peptides - Google Patents

Four branched dendrimer-peg for conjugation to proteins and peptides

Info

Publication number
ZA200804694B
ZA200804694B ZA200804694A ZA200804694A ZA200804694B ZA 200804694 B ZA200804694 B ZA 200804694B ZA 200804694 A ZA200804694 A ZA 200804694A ZA 200804694 A ZA200804694 A ZA 200804694A ZA 200804694 B ZA200804694 B ZA 200804694B
Authority
ZA
South Africa
Prior art keywords
conjugation
peptides
peg
proteins
branched dendrimer
Prior art date
Application number
ZA200804694A
Other languages
English (en)
Inventor
Ramon Hernandez Jose Angel
Castro Odio Fidel Raul
Saez Martinez Vivian Maria
Paez Meireles Rolando
Fernandez Sanchez Eduardo
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of ZA200804694B publication Critical patent/ZA200804694B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/325—Polymers modified by chemical after-treatment with inorganic compounds containing nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
ZA200804694A 2005-11-30 2008-05-29 Four branched dendrimer-peg for conjugation to proteins and peptides ZA200804694B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050241A CU23556A1 (es) 2005-11-30 2005-11-30 Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico

Publications (1)

Publication Number Publication Date
ZA200804694B true ZA200804694B (en) 2009-03-25

Family

ID=37672068

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200804694A ZA200804694B (en) 2005-11-30 2008-05-29 Four branched dendrimer-peg for conjugation to proteins and peptides

Country Status (17)

Country Link
US (1) US8703893B2 (zh)
EP (1) EP1967212B1 (zh)
JP (1) JP5123201B2 (zh)
KR (1) KR101134983B1 (zh)
CN (2) CN104906594B (zh)
AR (1) AR058841A1 (zh)
AU (1) AU2006319636B2 (zh)
BR (1) BRPI0604313A (zh)
CA (1) CA2631335C (zh)
CU (1) CU23556A1 (zh)
EG (1) EG26619A (zh)
MY (1) MY150739A (zh)
RU (1) RU2409389C2 (zh)
UA (1) UA91575C2 (zh)
UY (1) UY29981A1 (zh)
WO (1) WO2007062610A2 (zh)
ZA (1) ZA200804694B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5989294B2 (ja) * 2006-01-20 2016-09-07 スターファーマ・プロプライエタリー・リミテッドＳｔａｒｐｈａｒｍａ Ｐｔｙ Ｌｔｄ 修飾高分子
WO2009151687A2 (en) 2008-03-12 2009-12-17 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010054321A2 (en) 2008-11-07 2010-05-14 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
WO2010075423A2 (en) * 2008-12-23 2010-07-01 The Regents Of The University Of Michigan Dendrimer based modular platforms
WO2011059609A2 (en) * 2009-10-13 2011-05-19 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
WO2011059586A2 (en) 2009-10-30 2011-05-19 The Regents Of The University Of Michigan Multifunctional small molecules
WO2013085718A1 (en) 2011-12-08 2013-06-13 The Regents Of The University Of Michigan Multifunctional small molecules
US10406233B2 (en) 2011-12-21 2019-09-10 The Regents Of The University Of California Telodendrimers with enhanced drug delivery
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
KR102136336B1 (ko) * 2013-03-05 2020-07-22 한미약품 주식회사 생리활성 폴리펩타이드 결합체의 고수율 생산을 위한 개선된 제조 방법
EP2786766A1 (en) * 2013-04-05 2014-10-08 Ufpeptides S.r.l. Supramolecular aggregates comprising maleimido cores
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
CU20140003A7 (es) * 2014-01-08 2015-08-27 Ct De Inmunología Molecular Biofarmacuba Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
MX2017002140A (es) 2014-08-19 2017-08-21 Biogen Ma Inc Metodo de pegilacion.
CN107949565A (zh) * 2015-06-11 2018-04-20 安姆生物制药有限责任公司 聚乙二醇化粒细胞集落刺激因子(gcsf)
JP6841430B2 (ja) 2015-12-04 2021-03-10 全薬工業株式会社 血中滞留性を改善した抗ｉｌ−１７アプタマー
AU2017205694B2 (en) 2016-01-08 2022-05-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
EP4162955A1 (en) 2016-01-08 2023-04-12 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
EP3400020A1 (en) * 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
IL259659B (en) 2016-01-08 2022-08-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
EP3400065A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
WO2017118703A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
WO2018053316A1 (en) 2016-09-15 2018-03-22 The Regents Of The University Of California Improved hybrid telodendrimers
SG11201901534VA (en) 2016-09-29 2019-03-28 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
WO2019001473A1 (zh) * 2017-06-28 2019-01-03 北京键凯科技股份有限公司 一种树状多缩乙二醇衍生物及其制备方法和应用
CN109134282B (zh) * 2017-06-28 2021-03-16 北京键凯科技股份有限公司 一种树状多缩乙二醇衍生物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
ATE421535T1 (de) * 2000-10-16 2009-02-15 Chugai Pharmaceutical Co Ltd Peg-modifiziertes erythropoietin
US7026440B2 (en) * 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
CN1176137C (zh) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
CN1569892A (zh) * 2004-04-30 2005-01-26 新峰生物科技（上海）有限公司 多臂树杈型聚乙二醇与蛋白质或多肽的结合物及其制备方法
ITMI20020951A1 (it) 2002-05-06 2003-11-06 Univ Degli Studi Trieste Derivati multifunzionali del polietilenglicole loro preparazione ed impiego
TR201907313T4 (tr) * 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
EP1653996A2 (en) 2003-08-08 2006-05-10 Novo Nordisk Health Care AG Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
CN101072789B (zh) * 2004-01-08 2013-05-15 生物种属学股份公司 肽的o-连接的糖基化
ATE491475T1 (de) * 2004-07-16 2011-01-15 Nektar Therapeutics Konjugate enthaltend gm-csf und ein polymer
EP1848461A2 (en) 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
CA2601745A1 (en) 2005-02-16 2006-08-24 Novo Nordisk A/S Insulinotropic agents conjugated with structurally well defined branched polymers

Also Published As

Publication number Publication date
UA91575C2 (ru) 2010-08-10
EP1967212A2 (en) 2008-09-10
CU23556A1 (es) 2010-07-20
EG26619A (en) 2014-04-08
CN101389354A (zh) 2009-03-18
US8703893B2 (en) 2014-04-22
RU2008126209A (ru) 2010-01-10
KR101134983B1 (ko) 2012-04-09
CN104906594B (zh) 2016-12-28
KR20080072960A (ko) 2008-08-07
JP2009517414A (ja) 2009-04-30
US20090082537A1 (en) 2009-03-26
CA2631335A1 (en) 2007-06-07
JP5123201B2 (ja) 2013-01-23
WO2007062610A2 (es) 2007-06-07
MY150739A (en) 2014-02-28
AU2006319636A1 (en) 2007-06-07
UY29981A1 (es) 2007-06-29
AU2006319636B2 (en) 2012-10-18
BRPI0604313A (pt) 2007-01-30
EP1967212B1 (en) 2016-09-21
RU2409389C2 (ru) 2011-01-20
WO2007062610A3 (es) 2007-09-20
CN104906594A (zh) 2015-09-16
CA2631335C (en) 2013-07-16
AR058841A1 (es) 2008-02-27

Similar Documents

Publication Publication Date Title
EG26619A (en) PEG-quadrangle arbor polymer for binding to proteins and peptides
EP2102355A4 (en) PROTEINS AND PEPTIDES WITH EXTENDED ACTION AND METHODS OF PRODUCTION AND USE THEREOF
HRP20130720T1 (en) Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
EP1889908A4 (en) PROTEIN FUSED WITH ANTI-CD14 ANTIBODY
IL192104A0 (en) Stable protein formulations
EP2111237A4 (en) PEPTIDES FIXING TO FIBRIN AND CORRESPONDING CONJUGATES
ZA200709239B (en) Compositions for administering RNAIII-inhibiting peptides
EP1791855A4 (en) METHODS AND COMPOSITIONS ASSOCIATED WITH ARGONAUTE PROTEINS
IL205238A0 (en) Directed evolution using proteins comprising unnatural amino acids
ZA200810821B (en) New protein conjugates and methods for their preparation
PL1838341T3 (pl) Kompozycja szczepionki obejmująca białko wiążące fibronektynę lub peptyd wiążący fibronektynę
EP2234636A4 (en) FORMULATIONS OF STABILIZED PEPTIDES AND PROTEINS
EP1859063A4 (en) REPLIKIN PEPTIDES AND USES THEREOF
EP1945263A4 (en) THERAPEUTIC PEPTIDES BINDING TO METALS
GB0615635D0 (en) Immunogenic proteins and uses thereof
IL198659A (en) Targeted signals and recombinant proteins containing them
EP1953227A4 (en) BINDER OF LIPOPOLYSACCHARIDE OR LIPID A, AND NEW PEPTIDE
GB0526120D0 (en) Therapeutic peptides
GB0516527D0 (en) Peptides
EP1922328A4 (en) PEPTIDES TARGETED ON C PROTEIN KINASE ISOFORMS AND USE THEREOF
EP1939286A4 (en) NEW PEPTIDE
GB0521490D0 (en) RFamide-related peptide precursor proteins and RFamide peptides
GB0511846D0 (en) Protein crystal
EP2244725A4 (en) NOVEL PEPTIDES AND PROTEIN AND USE THEREOF
GB0511861D0 (en) Proteins